ClinicalTrials.govpublic full text
Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden
neoplasm metastasis, hepatic tumor burden, liver cancer, liver carcinoma, carcinoma, hepatic cancer, hepatic carcinoma, vda, vascular disrupting agent, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 855517
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.